glp-1/gip agonists GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Emerging Role of Dual GLP-1

Hiramatsu T, Ozeki A, Ishikawa H, Furuta S

6.2% said they might

Diabetes Investig

23-25 Despite those studies showing an overall long-term benefit of tight sugar control in preventing worse retinopathy, a small percentage of subjects had a paradoxical early worsening seen in the first year

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

In preclinical research models, glucagon receptor agonism has been shown to reduce hepatic fat content and increase resting energy expenditure, effects that are preserved when glucagon agonism is combined with GLP-1R and GIPR activation [3]